Almandil Noor B, Lodhi Rohit J, Ren Hongyan, Besag Frank M C, Rossolatos David, Ohlsen Ruth, Slomp Caitlin, Lapetina Diego L, Plazzotta Giona, Murray Macey L, Al-Sulaiman Abdulsalam A, Gringras Paul, Wong Ian C K, Aitchison Katherine J
Department of Clinical Pharmacy Research, Institute for Research and Medical Consultation, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Centre for Paediatric Pharmacy Research, Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom.
Mol Neuropsychiatry. 2018 Oct;4(2):111-117. doi: 10.1159/000490463. Epub 2018 Oct 5.
Data on baseline (antipsychotics-naïve) age, weight, and height, and change in these at 3 subsequent follow-up time points up to 313.6 days (95% CI 303.5-323.7) were collected from 181 risperidone-treated children and adolescents (mean age 12.58 years, SD 4.99, range 2.17-17.7) attending a pediatric neurology clinic in Saudi Arabia. Owing to differences in genotypic distributions in the subsamples, results are reported for the white Arab population ( = 144). Age- and gender-normed body mass index (BMI)-standardized scores (BMI ) were calculated (LMSgrowth program). Linear regression was performed for baseline weight and BMI , while change in BMI was assessed using random effects ordered logistic regression. The following single nucleotide polymorphisms (SNPs) were analyzed: rs7799039 in the promoter, rs1805094 (previously rs8179183), rs1137100 and rs1137101 in the , and rs1414334 in . We found a nominally significant association between rs7799309 and baseline weight, adjusting for height, age, gender, and diagnosis (A/G, = 0.035, β = -3.62 vs. G/G). The rs1137101 (G/G, = 0.018, odds ratio [OR] = 4.13 vs. A/A) and rs1805094 C allele carriers ( = 0.019, OR = 0.51) showed nominally significant associations with change in BMI categories. Our data support and replicate previous relevant associations for these variants (including with weight gain when on risperidone), whilst being the first report of such associations in patients of Arab ethnicity.
从沙特阿拉伯一家儿科神经科诊所的181名接受利培酮治疗的儿童和青少年（平均年龄12.58岁，标准差4.99，范围2.17 - 17.7岁）中收集了基线（未使用过抗精神病药物）时的年龄、体重和身高数据，以及在随后3个随访时间点（最长313.6天，95%置信区间303.5 - 323.7）这些数据的变化情况。由于子样本中基因型分布存在差异，报告的是阿拉伯白人人群（n = 144）的结果。计算了年龄和性别标准化的体重指数（BMI）标准化分数（BMI-SDS）（LMS生长程序）。对基线体重和BMI-SDS进行线性回归，同时使用随机效应有序逻辑回归评估BMI-SDS的变化。分析了以下单核苷酸多态性（SNP）：启动子中的rs7799039、中的rs1805094（先前的rs8179183）、rs1137100和rs1137101，以及中的rs1414334。我们发现，在校正身高、年龄、性别和诊断后，rs7799309与基线体重之间存在名义上显著的关联（A/G，p = 0.035，β = -3.62，对比G/G）。rs1137101（G/G，p = 0.018，优势比[OR] = 4.13，对比A/A）和rs1805094 C等位基因携带者（p = 0.019，OR = 0.51）与BMI-SDS类别变化存在名义上显著的关联。我们的数据支持并重复了先前关于这些变体的相关关联（包括使用利培酮时体重增加），同时这是此类关联在阿拉伯族裔患者中的首次报告。
